Table 2.
Trials Using Target Agents on Gene Mutation in Ovarian Cancer
| Drugs | Class | Combination Therapy | Status of Patients | Tumor Types | Gene Mutation | Target Molecule | Clinical Trial.org/Reference | Phase | Enrollment |
|---|---|---|---|---|---|---|---|---|---|
| APR-246 | PRIMA-1 | Cisplatin Doxorubicin | Resistant or sensitive | Serous | P53 | P53-MDM2 | [153] | / | 10 |
| AZD1775 | Inhibitor of WEE1 | Carboplatin | Resistant or refractory | Serous, OCCC, mucinous, others | P53, BRCA1/2 | P53 | NCT01164995154 | II | 23 |
| Adenoviral P53 (AdP53) | Cell-penetrating peptide | N/A | Resistant | Serous, others | P53 | P53 | [155] | I | 17 |
| ONYX-015 (dl1520) | Gene-deleted Adenovirus | N/A | Resistant recurrent | Serous | P53 | P53 | [156] | I | 16 |
| rAd-P53 SCH 58500 | Peptide | N/A | Recurrent | Serous | P53 | P53 | [157] | I/II | 36 |
| Enzastaurin | PI3K/AKT/PTEN pathway | N/A | Persistent or recurrent | Serous OCCC, others | P53 | P53 | [158] | II | 27 |
| Nutlin | MDM2 inhibitor | Cisplatin | Resistant | Serous, EnOC, mucinous | P53 | P53-MDM2 | [159] | / | 8 |
| RG7112 | MDM2 inhibitor | Monotherapy | N/A | Serous, OCCC | P53 | P53-MDM2 | [160] | I/II | 91 |
| Veliparib | PARPi | Monotherapy | Metastatic or unresectable | Serous, others | BRCA | BRCA | NCT01540565161 | II | 50 |
| Olaparib (AZD2281) | PARPi | Monotherapy | Platinum-sensitive | Serous, EnOC, others | BRCA | BRCA | NCT0187435378 | III | 295 |
| Niraparib | PARPi | Monotherapy | Platinum-sensitive | Serous, others | BRCA | BRCA | NCT0184727479 | III | 553 |
| Rucaparib | PARPi | Monotherapy | Platinum-sensitive | Serous, EnOC, others | BRCA | BRCA | NCT0196821380 | III | 564 |
| Iniparib | PARPi | Monotherapy | Platinum sensitivity | Serous, others | KRAS | BRCA | NCT00677079162 | II | 12 |
| Pilaralisib (SAR245408; XL147) | PI3K inhibitor | Monotherapy | Advanced or recurrent | Serous, OCCC, EnOC, others | PIK3CA | PIK3CA | NCT01013324163 | II | 67 |
| Pimasertib | MEK inhibitor | Voxtalisib | Advanced solid tumours | Serous, others | PIK3CA | PIK3CA | NCT01390818164 | Ib | 12 |
| Perifosine | Akt inhibitor | Docetaxel | Resistant or refractory recurrent | Serous, OCCC, EnOC, mucinous, others | PIK3CA/KRAS | PIK3CA/KRAS | [105,165] | I/II | 21 |
| Siltuximab | Chimeric (murine–human) monoclonal antibody | N/A | Resistant | N/A | KRAS | KRAS | [166] | I/II | 29 |
| Buparlisib | PI3K inhibitor) | Trametinib (MEK inhibitor). | N/A | Serous, OCCC, mucinous, others | KRAS | KRAS | NCT01155453167 | Ib | 21 |
Abbreviation: N/A, not available.